- Home
- PERF vs MOLN Comparison
PERF vs MOLN Comparison
Compare PERF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PERF | MOLN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | Taiwan | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 157.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PERF | MOLN |
|---|---|---|
| Price | $1.81 | $4.39 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 88.9K | 3.4K |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.89 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,900,999.00 | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $14.80 | $1,000.00 |
| P/E Ratio | $32.03 | ★ N/A |
| Revenue Growth | ★ 14.47 | N/A |
| 52 Week Low | $1.51 | $3.36 |
| 52 Week High | $3.44 | $5.91 |
Technical Indicators
Market Signals| Indicator | PERF | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 55.40 |
| Support Level | $1.75 | $3.98 |
| Resistance Level | $1.85 | $4.40 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 64.74 | 68.12 |
Price Performance
Historical ComparisonAbout PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.